嘉和生物-B发布2024年度业绩,净亏损5297.4万元,同比收窄92.2%

智通财经
30 Mar

智通财经APP讯,嘉和生物-B(06998)发布2024年度业绩,收益2.06亿元(人民币,下同),上年同期为0;该变动乃主要由于与TRC 2004, Inc.签订的许可及股权协议。净亏损5297.4万元,同比收窄92.2%。研发开支同比减少64.1%至2.028亿元,主要由于研发人员的雇员福利开支减少;集团的新药研发费及临床试验开支减少;及所用原材料及耗料减少。在报告期内集团进一步优化架构,并...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10